nanoparticles

Operational scale-up accelerates global growth strategy to increase regional access and technical support

Researchers designed a nanoparticle that inactivated a wide range of COVID-19 strains, potentially offering a broad-spectrum therapeutic approach.

Magnetic carbon nanotubes treat drug-resistant glioblastoma in mice, but hurdles remain for human translation.

Eye injections are the only way to treat diabetic retinopathy, but many refuse to get them. Now, eye drops and pills are on their way.

Researchers simultaneously increased the potency of a cancer drug while reducing both the required dose and the side effects, all by using a surprising new drug delivery vehicle: bacteria.

Join a panel of experts as they discuss nanoparticle technology and key considerations for nanoparticle-based drug delivery.  

Nanoparticles fuse with cells to deliver their gene or RNA therapy cargo, but some are better shuttles than others. Now, scientists have developed a way to find the best nanoparticles for the job.

Scientists and clinicians discussed their solutions for overcoming the challenge of getting past the blood-brain barrier in DDN’s first seminar.

Nanoparticles that successfully deliver drugs in mice often fail in humans. To understand how nanoparticles fare across different model species, scientists developed a high-throughput system to screen nanoparticles in mice with humanized livers with the hope of better predicting nanoparticles that work in humans.

Between invasive surgery or risky laser therapy, people suffering from severe eye floaters have no great treatment options. Now, with the development of a safer and less invasive nanoparticle-based therapy, people with floaters may finally get their vision and quality of life back.